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Background: Few studies have assessed whether the amelioration of the clinical signs of polycystic ovary
syndrome (PCOS) achieved by treatment leads to improvement in the health-related quality of life (HRQoL) of
patients. This study was aimed to examine the HRQoL of ethnic Chinese women with PCOS who received
metformin treatment.
Methods: This prospective study was conducted at a medical center in Taiwan. Study participants aged 18–45
years were diagnosed as having PCOS according to the Rotterdam criteria, and all received metformin treatment.
Their HRQoL was assessed using generic (WHOQOL-Bref) and PCOS-specific (Chi-PCOSQ) instruments. Mixed effect
models were used to examine the effects of metformin on repeatedly measured HRQoL. Additional analyses using
stratified patients characteristics (overweight vs. normal; hyperandrogenism vs. non-hyperandrogenism) were done.
Results: We recruited 109 participants (56 % were overweight, 80 % had hyperandrogenism). Among the domain
scores of WHOQOL-Bref, the psychological domain score was the lowest one (12.64 ± 2.2, range 4–20). Weight (3.25
± 1.59, range 1–7) and infertility (3.38 ± 1.93, range 1–7) domain scores were relatively low among the domain
scores of Chi-PCOSQ. Overweight and hyperandrogenic patients had significantly lower HRQoL as compared with
those of normal weight and non-hyperandrogenic patients, respectively. Metformin significantly improved the
physical domain of WHOQOL-Bref (p = 0.01), and the infertility (p = 0.043) and acne and hair loss aspects (p = 0.008)
of PCOS-specific HRQoL. In the subgroup analysis, significantly improved HRQoL following metformin treatment
appeared for only overweight and hyperandrogenism subgroups.
Conclusions: Metformin might improve health-related quality of life of polycystic ovary syndrome women by
ameliorating psychological disturbances due to acne, hair loss and infertility problems, especially for overweight
and hyperandrogenic patients.
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Health-related quality of life (HRQoL) is generally defined
as the functional effect of a clinical condition and/or its
treatments upon a patient, which is subjective and multi-
dimensional, including physical function, psychological
state, and social interactions [1]. With medical advances
that have improved life expectancy, population health is
measured not only on the basis of saving lives but also in
terms of improving the quality of life. The ultimate goal of
healthcare is to improve, restore, or preserve the quality of
life of patients [2]; survival per se may no longer be per-
ceived to be only important outcome. Hence, in addition
to traditional measures of health (e.g., survival), HRQoL is
an important indicator that captures the burden of illness.
For chronic illnesses or clinical conditions for which there
is no cure, it is critical to provide therapy that makes
patients feel better. To assess HRQoL, the degree to which
the disease or its treatment influences the patient’s life is
quantified from an individual’s perspective. Assessing
HRQoL helps healthcare providers understand whether
patients are satisfied with their health and associated
treatments. Also, HRQoL is important to consider when
evaluating various symptom management plans [3] and
disease treatments [4], especially when they provide similar
effects on life expectancy. According to U.S. Food and Drug
Administration’s guidance for industry, HRQoL can be used
as a clinical outcome to claim the effect of treatment [5].
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in reproductive-aged women [6]. Clin-
ical presentations associated with PCOS, such as over-
weight/obesity, hirsutism, acne, hair loss/ androgenic
alopecia, oligomenorrhea, amenorrhea and infertility and
can lead to mood disturbances, affect the emotional well-
being as well as sexual satisfaction of women, and cause a
reduction in the HRQoL of patients [7, 8]. Obesity, clinical
signs of hyperandrogenism (i.e., acne, hair loss), and infer-
tility are the main contributors to psychological morbidity
[9–11]. The HRQoL of women with PCOS has been in-
vestigated in several studies for some countries [7, 12, 13];
however, data on the HRQoL of Chinese women with
PCOS is limited. It has been recognized that clinical
representations of PCOS vary with culture and ethnicity
[14], and may thus have different impacts on HRQoL. For
example, the prevalence of hirsutism and obesity in
Chinese women with PCOS appears to be lower than that
from Caucasians patients [14]; contrarily, acne and hair
loss were common problems reported in ethnic Chinese
women with PCOS [15]. Therefore, assessing the impact
of PCOS on the HRQoL of patients across ethnic groups
is important.
Metformin, which increases insulin sensitivity, is one
of common treatments for PCOS in Taiwan. Some stud-
ies showed that metformin improves the body weight,
insulin sensitivity, acne, hirsutism, and menstrual cycleof women with PCOS, and that the effects of metformin
may vary depending on a patient’s characteristics (i.e.,
obesity, hyperandrogenism) [16–19]. However, other
research found that, among obese women with PCOS,
metformin may not lower body weight or improve the
menstrual cycle and weight loss alone through lifestyle
modifications improves menstrual function [20]. Of
notice, previous research primarily focused on clinical
effectiveness of metformin [16–20], but only a few stud-
ies [7, 21] have determined whether the amelioration of
the clinical signs of PCOS achieved by treatment leads
to improvement in the HRQoL of patients. Therefore,
this study aimed to assess the impact of PCOS on the
HRQoL of ethnic Chinese women with PCOS and the
effects of metformin on the HRQoL of PCOS patients.
Methods
This was a prospective observational study. Before com-
mencement of the study, permission was obtained from
the Institutional Review Board of National Cheng Kung
University Hospital, Tainan, Taiwan (A-ER-103-287).
Participants
All participants were recruited from the Department of
Obstetrics and Gynecology at National Cheng Kung
University Hospital during February to August, 2015.
They met the following inclusion criteria: (1) aged 18–45
years, (2) diagnosed with PCOS according to the Rotterdam
criteria, defined as the presence of at least two of the
following three criteria: (i) oligo-anovulation (a cycle
length of > 35 days or amenorrhoea), (ii) clinical hyperan-
drogenism (hirsutism recorded as m-FG score of ≥ 6 with/
without acne or androgenic alopecia) and/or biochemical
hyperandrogenism (total testosterone level of more than
0.95 ng/mL), and (iii) polycystic ovaries (≥12 follicles
measuring 2–9 mm in diameter, or ovarian volume >
10 ml in at least one ovary) [22], and (3) competent in
Mandarin Chinese. We excluded those: (1) diagnosed with
similar clinical presentations (e.g., hyperprolactinemia,
thyroid dysfunction, Cushing syndrome), (2) diagnosed
with diabetes or had fasting plasma glucose ≥ 126 mg/dL
or 2-h glucose ≥ 200 mg/dL before PCOS diagnosis,
(3) taking any medications that may influence insulin level
or contraceptive pills at 3 months before PCOS diagnosis,
(4) suffered a major traumatic event at least 6 months
prior to the data collection (i.e., divorce, separation, or
death of intimate partner or relatives). This is because the
people experiencing these life events are likely to have
negative emotions (e.g., depression, sad, anxiety), which
may affect their psychological well-being [23–25]. All par-
ticipants gave a written informed consent regarding their
willingness to participate in the research. The second author
used the questionnaires to face-to-face interview each par-
ticipant at every time when they returned for a visit during
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uled for a following visit within 1 to 2 months. The author
confirmed that all participants had completed all study
questionnaires and demographic questions measuring age,
gender, residence, highest education, disease duration,
comorbidities, and exercise behavior. Routine physical
examination (i.e., weight, height, PCOS-specific physical
appearance: acne, hirsutism) was conducted at each visit.
Overweight was defined using body mass index (BMI)
calculated by weight and height, and a BMI ≥25 kg/m2
suggests overweight. A blood test was taken at each visit
to determine hormone and glycemic levels.
Once PCOS was diagnosed, all patients were treated
with metformin (500 mg TID). Patients who can not
tolerate the immediate-release formulation (i.e., due to
gastrointestinal intolerance side effects) could reduce the
dose of metformin (from TID to BID) or were switched
to extended-release metformin.
Study measurements
The following questionnaires were administered to each
participant before, during, and after 6 months of metformin
treatment.
Health-related quality-of-life questionnaire for women
with polycystic
Ovary Syndrome (PCOSQ) [26] is a disease-specific
HRQoL questionnaire that contains 26 questions using a
seven-point rating scale (1: maximum impairment and 7:
no impairment of HRQoL) in the following five domains:
emotions (7 items), hair growth (5 items), body weight
(5 items), infertility (5 items), and menstruation (4 items).
The psychometric properties of the PCOSQ showed
good test-retest reliability (all intraclass correlation coeffi-
cients > 0.8), acceptable internal reliability (all Conbroach’s
α values > 0.7), and satisfactory concurrent validity with
the SF-36 [27]. The present study used a Chinese version
of PCOSQ (Chi-PCOSQ), which was recently developed
by Ou et al. [15]. Its score was shown to be reliable and
valid in a sample of Chinese-speaking women with PCOS.
WHOQO-Bref [28] is a short version of the World
Health Organization Quality of Life (WHOQOL)-100. It
has 26 items. The Taiwan version of WHOQOL-Bref
additionally includes two domestic items. There are 26
items distributed into four domains: physical health
(7 items), psychological health (6 items), social relations
(4 items), and environment (11 items). Items are rated
on a 5-point Likert scale (low score of 1 to high score of 5).
The mean score for each domain is calculated, resulting in
a mean score per domain that is between 4 and 20. The
total score of WHOQOL-Bref is the sum of all domain
scores; it ranges from 16 to 80, with a higher score indicat-
ing better quality of life. Internal consistency (Cronbach’s
α = 0.70–0.91), test-retest reliability (r = 0.76–0.80), andconstruct validity (comparative fit index = 0.89) have been
established for the Taiwan version scores [29].
MMSA-8 In order to account for the effect of medica-
tion behavior, the Morisky 8-item medication adherence
scale (MMAS-8) [30] was applied to measure medication
adherence. The MMAS-8 is one of the most commonly
used self-report adherence questionnaires. The Chinese
version of MMAS-8 has been validated among a con-
venience sample of 176 patients in China [31]. The scale
showed acceptable internal consistency (Cronbach’s α =
0.77) and test-retest reliability (r = 0.88), and good con-
struct validity.
Statistical analyses
Descriptive analyses were used to present the demo-
graphics of the study sample and the WHOQOL-Bref
and Chi-PCOSQ total and domain scores. Repeated
measures analysis of variance (ANOVA) was performed
to detect the changes in the HRQoL outcomes along
with treatment time between subgroups. Mixed effect
models were applied to assess the effects of metformin
on repeated outcomes measures (including total and
domain scores of WHOQOL-Bref and Chi-PCOSQ). Study
patients were stratified by BMI (overweight vs. normal)
and clinical and/or biochemical hyperandrogenism. Mixed
effect models were applied within each subgroup to detect
significant change in the HRQoL following metformin
treatment. The SAS 9.4 was utilized for all aforementioned
analyses.
Results
A total of 109 eligible women were enrolled in the study,
with average follow-up time of 5.18 (±1.06) months.
There were 83 patients who completed 6 months of
follow-up, 12 patients who were lost follow-up, 11 pa-
tients who got pregnancy, and 3 patients who switched
to oral contraceptive pills. The mean age of the partici-
pants was 28.3 years; 56 % of them were overweight and
80 % had hyperandrogenism. The detailed baseline char-
acteristics are presented in Table 1.
The changes of HRQoL were revealed by the total and
domain scores of both WHOQOL-Bref and Chi-PCOSQ
within the period of metformin treatment (Table 2).
Overall, PCOS patients had the lowest score in the
psychological aspect of HRQoL, with similar trends
found within subgroups. These imply higher impact of
psychological disturbances to patients’ quality of life.
Overweight patients had significantly lower HRQoL
(relatively poorer quality of life) as compared to that of
normal weight patients in WHOQOL-Bref scores. Re-
peated measures ANOVA indicated that the changes in
psychological and social domain scores along with treat-
ment duration between overweight and normal weight
subgroups were significantly different (p = 0.027 and
Table 1 Demographics of study population
Characteristics
All (n = 109)
Subgroups
Normal weight
(BMI < 25 kg/m2)
(n = 48)
Overweight






Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age (years) 28.3 ± 5.1 27.12 ± 4.47 29.3 ± 5.47 27.6 ± 4.9 28.0 ± 5.2
BMI (kg/m2) 26.8 ± 6.4 21.1 ± 1.9 31.6 ± 4.6** 23.8 ± 4.9 27.6 ± 6.5*
Systolic BP (mmHg) 121.9 ± 16.3 113.1 ± 12.3 129.2 ± 15.7** 110.3 ± 11.3 125.2 ± 16.1*
Diastolic BP (mmHg) 76.4 ± 13.7 69.8 ± 9.7 81.9 ± 14.3** 69.4 ± 9.9 78.4 ± 14.1*
mF-G score 3.2 ± 2.1 2.8 ± 2.3 3.5 ± 1.9 2.5 ± 1.5 3.4 ± 2.2
Hormones Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
TSH (μIU/mL) 1.72 ± 0.91 1.40 ± 0.72 2.00 ± 0.87* 1.49 ± 0.74 1.79 ± 0.95
LH (mIU/mL) 8.78 ± 4.82 11.02 ± 5.40 6.78 ± 3.17** 11.28 ± 5.80 8.01 ± 4.25*
FSH (mIU/mL) 5.29 ± 2.07 5.50 ± 1.93 5.10 ± 2.20 5.24 ± 2.12 5.31 ± 2.08
E2 (pg/mL)** 40.13 ± 41.74 36.41 ± 27.37 43.56 ± 51.73 40.21 ± 31.34 40.11 ± 44.56
PRL (ng/mL) 9.12 ± 3.92 8.90 ± 3.59 9.31 ± 4.24 9.48 ± 4.01 9.01 ± 3.93
TT (ng/mL) 0.58 ± 0.32 0.57 ± 0.37 0.59 ± 0.27 0.54 ± 0.24 0.59 ± 0.34
Glycemic parameters Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
2-h glucose (mg/dL) 113.2 ± 29.0 103.6 ± 26.9 121.2 ± 28.6* 105.4 ± 24.0 115.4 ± 30.1
2-h insulin (μIU/mL) 89.8 ± 91.1 46.2 ± 25.3 126.9 ± 109.2** 52.8 ± 50.5 100.0 ± 97.3*
Clinical presentation n (%) n (%) n (%) n (%) n (%)
Hirsutism 12 (16.2) 5 (14.7) 7 (17.5) 0 (0.0) 12 (20.7)
Acne 36 (48.6) 16 (47.1) 20 (50.0) 0 (0.0) 36 (62.1)**
Weight gain 33 (44.6) 11 (32.4) 22 (55.0) 5 (31.3) 28 (48.3)
Hair loss 40 (54.1) 15 (44.1) 25 (62.5) 0 (0.0) 40 (69.0)**
Impaired glucose intolerance 14 (18.9) 4 (11.8) 10 (25.0) 1 (6.3) 13 (22.4)
Insulin resistance 54 (73.0) 20 (58.8) 34 (85.0)* 8 (50.0) 46 (79.3)*
Abbreviations: BMI body mass index, BP blood pressure, LH luteinizing hormone, FSH follicle stimulating hormone, E2 estradiol, PRL prolactin, TT total testosterone,
mF-G modified Ferriman-Gallwey, SD standard deviation
*p < 0.05, **p < 0.001
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ively). Hyperandrogenic patients had significantly lower
HRQoL as compared to that of those without hyperan-
drogenism. The changes in total score and physical,
psychological, and social domain scores along with treat-
ment time between hyperandrogenism and non- hyperan-
drogenism subgroups were significantly different (repeated
measures ANOVA showed p = 0.014, 0.012, 0.013, and
0.015 for total score and physical, psychological, and social
domain scores, respectively).
PCOS patients had the lowest score on the weight do-
main of Chi-PCOSQ and the highest score on the body
hair domain. This means that weight associated psycho-
logical disturbances had the greatest impact on patients’
HRQoL, while patients had less impact of body hair
problems on their HRQoL. Overweight patients had sig-
nificantly lower PCOS-specific HRQoL (relatively poorer
PCOS-specific quality of life) as compared to that ofnormal weight patients. Repeated measures ANOVA
indicated that the change in weight domain score along
with treatment duration between overweight and normal
weight subgroups was significantly different (p < 0.0001).
Also, hyperandrogenic patients had significantly lower
PCOS-specific HRQoL as compared to that of non-
hyperandrogenic patients. The change in acne and hair
loss domain score along with treatment time between
hyperandrogenism and non- hyperandrogenism subgroups
was significantly different (p < 0.0005), implying that the
improved HRQoL, especially on acne and hair loss aspects,
was greater in hyperandrogenic patients than that in
non-hyperandrogenic patients.
Table 3 shows that the physical domain of WHOQOL-
Bref significantly improved with treatment time (p = 0.01).
Overweight patients had significantly improved physical
domain scores during the treatment period, whereas no
improvement trend was found for normal weight patients.














Visit 1 (baseline) 55.05 ± 6.75 56.51 ± 6.27 53.80 ± 6.97 58.34 ± 6.27 54.14 ± 6.65
Visit 2 (1st -2nd month of treatment) 56.19 ± 7.38 57.54 ± 7.15 55.05 ± 7.48 60.87 ± 6.98 55.90 ± 7.02
Visit 3(3rd- 4th month of treatment) 55.25 ± 7.81 57.00 ± 7.53 53.72 ± 7.85 59.91 ± 7.62 54.16 ± 7.52
Physical domain (4–20)
Visit 1 14.38 ± 1.78 14.52 ± 1.71 14.26 ± 1.86 15.11 ± 1.64 14.18 ± 1.78
Visit 2 14.97 ± 1.90 15.03 ± 1.89 14.91 ± 1.93 16.00 ± 1.87 14.68 ± 1.82
Visit 3 14.78 ± 1.96 14.98 ± 2.12 14.60 ± 1.82 15.79 ± 1.70 14.54 ± 1.95
Psychological domain (4–20)
Visit 1 12.64 ± 2.27 13.12 ± 2.04 12.23 ± 2.40 13.46 ± 2.10 12.41 ± 2.29
Visit 2 12.77 ± 2.37 13.25 ± 2.31 12.35 ± 2.37 14.29 ± 2.27 12.34 ± 2.24
Visit 3 12.68 ± 2.48 13.36 ± 1.91 12.09 ± 2.78 14.06 ± 2.56 12.35 ± 2.37
Social domain (4–20)
Visit 1 14.01 ± 1.85 14.47 ± 1.58 13.63 ± 2.00 14.94 ± 1.48 13.76 ± 1.88
Visit 2 14.27 ± 2.17 14.82 ± 1.98 13.80 ± 2.23 15.69 ± 1.85 13.88 ± 2.09
vVisit 3 13.88 ± 2.16 14.41 ± 1.99 13.42 ± 2.23 15.27 ± 2.00 13.55 ± 2.08
Environment domain (4–20)
Visit 1 14.02 ± 1.90 14.40 ± 1.91 13.69 ± 1.84 14.83 ± 1.86 13.79 ± 1.86
Visit 2 14.19 ± 2.01 14.43 ± 1.93 13.99 ± 2.08 14.89 ± 2.06 14.00 ± 1.97
Visit 3 13.92 ± 2.13 14.26 ± 2.31 13.62 ± 1.95 14.79 ± 1.97 13.71 ± 2.13
Chi-PCOSQ
Total scores (6–42)
Visit 1 (baseline) 24.53 ± 7.61 25.37 ± 7.56 23.82 ± 7.68 27.68 ± 6.50 23.66 ± 7.72
Visit 2 (1st -2nd month of treatment) 25.41 ± 7.33 26.47 ± 7.40 24.51 ± 7.25 28.31 ± 7.41 24.61 ± 7.17
Visit 3(3rd- 4th month of treatment) 25.63 ± 7.21 27.37 ± 7.88 24.12 ± 6.32 28.58 ± 7.60 24.94 ± 7.02
Weight domain (1–7)
Visit 1 3.25 ± 1.59 3.91 ± 1.58 2.67 ± 1.38 3.69 ± 1.18 3.12 ± 1.68
Visit 2 3.34 ± 1.61 4.17 ± 1.59 2.63 ± 1.25 3.98 ± 1.38 3.16 ± 1.62
Visit 3 3.43 ± 1.49 4.20 ± 1.55 2.76 ± 1.08 3.89 ± 1.25 3.32 ± 1.54
Infertility domain (1–7)
Visit 1 3.38 ± 1.93 3.27 ± 1.78 3.48 ± 2.07 3.88 ± 2.17 3.25 ± 1.86
Visit 2 3.59 ± 2.01 3.43 ± 1.84 3.73 ± 2.16 3.75 ± 2.36 3.55 ± 1.93
Visit 3 3.76 ± 1.91 3.84 ± 1.85 3.70 ± 2.00 4.00 ± 2.18 3.71 ± 1.87
Menstrual domain (1–7)
Visit 1 3.67 ± 1.53 3.67 ± 1.48 3.68 ± 1.60 3.55 ± 1.42 3.71 ± 1.57
Visit 2 3.94 ± 1.45 3.98 ± 1.40 3.92 ± 1.50 3.81 ± 1.35 3.98 ± 1.48
Visit 3 3.92 ± 1.31 4.10 ± 1.30 3.76 ± 1.31 4.04 ± 1.38 3.89 ± 1.31
Emotions domain (1–7)
Visit 1 4.65 ± 1.77 4.72 ± 1.59 4.59 ± 1.97 4.90 ± 1.77 4.58 ± 1.78
Visit 2 4.84 ± 1.65 4.93 ± 1.53 4.76 ± 1.76 5.13 ± 1.69 4.76 ± 1.64
Visit 3 4.79 ± 1.71 5.04 ± 1.78 4.47 ± 1.64 5.05 ± 1.86 4.73 ± 1.69
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Table 2 Change in HRQoL in Chinese women with PCOS along with metformin treatment duration (Continued)
Body hair domain (1–7)
Visit 1 5.37 ± 1.60 5.45 ± 1.73 5.30 ± 1.50 6.19 ± 0.99 5.14 ± 1.67
Visit 2 5.38 ± 1.55 5.61 ± 1.56 5.18 ± 1.53 6.20 ± 1.17 5.15 ± 1.57
Visit 3 5.31 ± 1.62 5.67 ± 1.65 5.00 ± 1.54 6.02 ± 1.27 5.14 ± 1.65
Acne & Hair loss domain (1–7)
Visit 1 4.21 ± 1.63 4.34 ± 1.57 4.10 ± 1.69 5.48 ± 1.16 3.86 ± 1.57
Visit 2 4.32 ± 1.58 4.35 ± 1.66 4.29 ± 1.53 5.44 ± 1.37 4.01 ± 1.50
Visit 3 4.41 ± 1.40 4.50 ± 1.60 4.34 ± 1.22 5.58 ± 1.33 4.14 ± 1.28
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subgroups, significantly improved physical domain scores
were found only for the former. Table 4 indicates that the
infertility and acne and hair loss domains of Chi-PCOSQ
significantly improved with treatment time (p < 0.05).
Overweight patients had significantly improved acne and
hair domain scores, and hyperandrogenic patients had sig-
nificantly improved infertility and acne and hair domain








Visit 2 (reference = visit 1) −0.93 (1.04) 0.47 (0.77)
Visit 3 (reference = visit 1) 0.06 (0.94) 0.07 (0.75)
Physical domain
Treatment time p = 0.010
Visit 2 (reference = visit 1) 0.58 (0.20)* 0.50 (0.29)
Visit 3 (reference = visit 1) 0.54 (0.20)* 0.50 (0.29)
Psychological domain
Treatment time
Visit 2 (reference = visit 1) −0.90 (0.06) −0.17 (0.34)
Visit 3 (reference = visit 1) −0.06 (0.39) −0.14 (0.33)
Social domain
Treatment time
Visit 2 (reference = visit 1) −0.61 (0.39) 0.10 (0.31)
Visit 3 (reference = visit 1) −0.31 (0.35) −0.31 (0.30)
Environment domain
Treatment time
Visit 2 (reference = visit 1) 0.13 (0.15) −0.07 (0.23)
Visit 3 (reference = visit 1) 0.07 (0.16) −0.06 (0.22)
Note: Visit 1 is 1st office visit when patients were diagnosed with PCOS (baseline). O
2nd office visit (1st-2nd month of treatment). Visit 3 was 3rd office visit (3rd- 4th m
adherence via the Morisky 8-item medication adherence scale
Abbreviations: HRQoL health-related quality of life, SE standard error
*p < 0.05Discussion
There is a lack of research that assesses HRQoL in eth-
nic Chinese women with PCOS. Also, clinical evidence
showing the effect of treatment for PCOS women on
HRQoL is scarce. The present study found that psycho-
logical disturbances due to PCOS associated problems
(i.e., acne, hair loss, infertility) may lead to a reduction
in the HRQoL for ethnic Chinese women with PCOS.








−1.72 (1.44) 1.49 (1.26) 0.79 (0.56)
−0.27 (1.45) 0.52 (1.30) 0.70 (0.56)
p = 0.036 p = 0.015
0.57 (0.28)* 0.62 (0.50) 0.55 (0.22)*
0.64 (0.27)* 0.29 (0.51) 0.60 (0.22)*
−1.49 (0.57) 0.63 (0.58) −0.16 (0.23)
−0.76 (0.57) 0.17 (0.60) 0.002 (0.23)
0.18 (0.24) −0.83 (0.69) 0.05 (0.21)
0.14 (0.25) −0.02 (0.63) −0.14 (0.21)
0.29 (0.21) −0.34 (0.27) 0.23 (0.18)
0.17 (0.22) −0.16 (0.28) 0.10 (0.18)
nce PCOS was diagnosed, patients started metformin treatment. Visit 2 was
onth of treatment). The analysis was adjusted for the effect of medication















Visit 2 (reference = visit 1) 0.44 (0.56) 0.75 (0.86) 0.20 (0.75) −0.58 (0.89) 0.61 (0.66)
Visit 3 (reference = visit 1) 1.25 (0.56) 1.77 (0.84) 0.80 (0.78) 0.11 (0.92) 1.45 (0.66)*
Weight domain
Treatment time
Visit 2 (reference = visit 1) −0.06 (0.14) 0.11 (0.22) −0.18 (0.19) −0.04 (0.28) −0.07 (0.17)
Visit 3 (reference = visit 1) 0.12 (0.15) 0.15 (0.21) 0.10 (0.20) −0.01 (0.29) 0.15 (0.17)
Infertility domain
Treatment time p = 0.043 p = 0.048
Visit 2 (reference = visit 1) 0.25 (0.18) 0.34 (0.23) 0.15 (0.29) −0.06 (0.33) 0.32 (0.21)
Visit 3 (reference = visit 1) 0.46 (0.18)* 0.34 (0.24) 0.59 (0.28)* 0.12 (0.34) 0.52 (0.21)*
Menstrual domain
Treatment time
Visit 2 (reference = visit 1) 0.10 (0.18) 0.21 (0.29) 0.02 (0.24) 0.26 (0.39) 0.08 (0.20)
Visit 3 (reference = visit 1) 0.19 (0.18) 0.36 (0.27) 0.04 (0.25) 0.58 (0.41) 0.11 (0.20)
Emotions domain
Treatment time
Visit 2 (reference = visit 1) 0.07 (0.15) 0.15 (0.21) 0.01 (0.21) 0.82 (0.33)* 0.04 (0.18)
Visit 3 (reference = visit 1) 0.14 (0.15) 0.30 (0.21) 0.003 (0.21) 0.43 (0.29) 0.13 (0.18)
Body hair domain
Treatment time
Visit 2 (reference = visit 1) 0.03 (0.14) 0.18 (0.19) −0.08 (0.20) −0.34 (0.20) 0.10 (0.17)
Visit 3 (reference = visit 1) 0.02 (0.14) 0.24 (0.18) −0.16 (0.21) −0.37 (0.21) 0.10 (0.17)
Acne & Hair loss domain
Treatment time p = 0.008 p = 0.043 p = 0.007
Visit 2 (reference = visit 1) −0.51 (0.28) −0.10 (0.19) 0.01 (0.20) −0.46 (0.18)* −0.55 (0.35)
Visit 3 (reference = visit 1) 0.45 (0.26) 0.08 (0.19) 0.33 (0.21) −0.28 (0.19) 0.71 (0.32)*
Note: Visit 1 is 1st office visit when patients were diagnosed with PCOS (baseline). Once PCOS was diagnosed, patients started metformin treatment. Visit 2 was
2nd office visit (1st-2nd month of treatment). Visit 3 was 3rd office visit (3rd- 4th month of treatment). The analysis was adjusted for the effect of medication
adherence via the Morisky 8-item medication adherence scale
Abbreviations: PCOS polycystic ovary syndrome, HRQoL Health related Quality of life, SE standard error
*p < 0.05
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and non-hyperandrogenic counterparts. Metformin may
provide benefits to the HRQoL of PCOS women by ameli-
orating psychological disturbances due to acne, hair loss
and infertility problems, especially for the patients who
present overweight and hyperandrogenism.
HRQoL in PCOS patients treated with metformin
Few studies [7, 21] have assessed treatment effects on
HRQoL outcomes for PCOS women. Hahn et al. [21]
examined the HRQoL of 64 German women with PCOSwith 6-month treatment of metformin. They found
positive effects of metformin on HRQoL outcomes,
especially on psychosocial, emotional, and psychosexual
aspects of well-being. The present study also observed
that the emotions domain of HRQoL was generally
improved following treatment, although the change was
not statistically significant.
Acne and hair loss/androgenetic alopecia could in-
crease women’s self-consciousness, feelings of unattract-
iveness and emotional distress [10, 11]. Previous studies
have shown that metformin alleviates clinical signs of
Ou et al. Health and Quality of Life Outcomes  (2016) 14:119 Page 8 of 10hyperandrogenism (i.e., acne) [32, 33]. However, no stud-
ies assessed potential benefits of metformin on HRQoL
outcomes associated with the improved clinical signs of
hyperandrogenism (i.e., acne). This is in part because acne
and hair loss issues are not included in the original
PCOSQ [26], which is the most commonly used PCOS-
specific HRQoL instrument. The present study used the
Chi-PCOSQ, which is a Chinese version of PCOSQ and
contains the acne and hair loss domain, and found signifi-
cantly relieved acne and hair loss associated psychological
disturbances (i.e., worried, embarrassed) after metformin
treatment. In fact, more than half of study participants
having acne or hair loss problem at baseline reported no
these problems after 3 – 4 months of treatment, which is
even profound in the hyperandrogenism subgroup; 81 %
of hyperandrogenism patients without acne or hair loss
problems at 3 – 4 months of treatment. Thus, the im-
proved clinical signs of hyperandrogenism as a result of
metformin may lead to satisfactory HRQoL of PCOS
patients.
Previous research has supported that insulin sensi-
tizers (e.g., metformin) provide fertility benefits to PCOS
patients (i.e., improve pregnancy rate [16]), especially
those with hyperinsulinemia or insulin resistance, which
could be responsible for the abnormal ovarian response
[34]. Guyatt et al.’s study observed significant improve-
ments in the infertility aspect of the PCOS-specific
HRQoL (measured via PCOSQ) after 44 weeks of trogli-
tazone treatment [7]. Troglitazone, an insulin sensitizer
like metformin, was previously used in PCOS. The
present study also observed improved infertility aspect
of PCOS-specific HRQoL, especially in hyperandrogenic
patients. Thus, the amelioration of ovulation problems
achieved by insulin sensitizers (i.e., troglitazone, metfor-
min) may alleviate emotional distress due to infertility
and thus contribute to the improvement of the HRQoL
of PCOS patients. The infertility domain in Chi-PCOSQ
consists of three items: “concerned about infertility
problems”, “afraid of not being able to have children”,
and “sad because of infertility problems”. These items
are associated with patient’s psychological concerns
about fertility. Although we did not find a significantly
increase pregnancy rate in our reproductive-aged partici-
pants after treatment, patient’s perceived benefits from
metformin and reduced perceived susceptibility to infer-
tility after treatment [35] may lead to the improved fer-
tility aspect of HRQoL that we observed.
Metformin is recommended as one of treatment
options in PCOS women, especially for those who
present obesity, hyperandrogenism, insulin resistance or
hyperinsulinemia [18]. Consistently, our results showed
significant effects of metformin on HRQoL of PCOS
patients, especially in overweight and hyperandrogenic
patients. Also, insulin resistance is one of importantcharacteristics for metformin efficacy [33]. Our previous
study showed that with metformin treatment, over-
weight PCOS women (BMI ≥ 25 kg/m2) had a significant
reduction in body weight as compared to those with
normal weight and patients with insulin resistance had a
significantly improved 2-h insulin level as compared to
those without insulin resistence [19]. In the present
study, we found that the prevalence of insulin resistance
in the overweight group was higher than that in the nor-
mal weight group (85 versus 58 %). This may be another
reason why positive effect of metformin on HRQoL out-
comes was observed in overweight patients, but not in
normal weight patients. Moreover, it has been argued
that the combination of menstrual problems, hyperan-
drogenism and anovulation can be positively affected by
metformin treatment [18]. This may explain our findings
showing that metformin provided significant benefits in
HRQoL outcomes for PCOS women with hyperandro-
genism, especially in terms of mitigating the burden of
acne and hair loss, and infertility associated psycho-
logical distress on the HRQoL of patients.
Importance of study findings to clinicians and patient
care
Considerable burden of psychological disturbances due
to acne, hair loss and infertility problems on the HRQoL
of ethnic Chinese women with PCOS requires healthcare
providers’ attention. Regularly assessing the HRQoL of
PCOS patients through generic and/or disease-specific
HRQoL instruments would help clinicians detect any
changes in patients’ HRQoL due to clinical signs of
PCOS or treatment interventions. As a supplement to
lifestyle changes (e.g., exercise and weight control), the
amelioration of clinical signs of PCOS achieved by met-
formin may lead to improvement in HRQoL. Also,
PCOS patients who present overweight or hyperandro-
genism may receive the most benefit from metformin
treatment on their HRQoL.
Potential limitations
Several limitations of this study need to be addressed.
First, all participants were from one medical center in
southern Taiwan. Our findings may be applicable to only
a subset of Chinese women. Ethnically Chinese people
are distributed over a large geographic area, and are
likely to have differences in dietary habits, physical activ-
ity, and even treatment approaches. Second, all partici-
pants knew that they were receiving metformin and
thus, the improved HRQoL which we observed may be
in part because of their motivation to improve. Third,
because this was an observational study and all partici-
pants received metformin treatment after PCOS diagno-
sis, this study did not compare other treatments for
PCOS (e.g., oral contraceptives, as active control) or
Ou et al. Health and Quality of Life Outcomes  (2016) 14:119 Page 9 of 10have a placebo control group. However, other types of
treatment (e.g., clomiphene) for PCOS may also provide
benefits (e.g., reproductive) for the HRQoL of patients.
Fourth, because this was not a randomized design study,
selection bias could not be avoided. Moreover, our
results were based on patients’ reporting of HRQoL
outcomes, and thus, self-reporting bias could not be
avoided. Lastly, the present study did not include object-
ive measures (e.g., pregnancy rate) as indicators for
metformin treatment. So, improvement in subjective
outcomes (e,g, HRQoL) may not be explained as the
result of changes in objective measures of clinical out-
comes. However, we did observed clinical improvement in
patient’s body weight and acne and hair loss problems.
Conclusions
This is the first study to apply Chi-PCOSQ to assess the
HRQoL of ethnic Chinese with PCOS and to evaluate
the HRQoL outcomes of PCOS patients after metformin
treatment. The results provide important clinical impli-
cations for the care of PCOS patients and suggest that
developing interventions for improving the HRQoL of
PCOS patients is needed. Future studies from other
countries/ethnicity are warranted to evaluate the influ-
ence of treatment on the HRQoL outcomes of PCOS
women.
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